InterveXion Therapeutics LLC
Directory listingDirectory record status
These labels describe this UNITEMFG record. They do not guarantee current capabilities, certifications, capacity, quality, or fit for a specific job.
- Directory listing
- Listed
- Ownership
- Unclaimed
- Evidence reviewed
- Not recorded
- Last evidence review
- Not recorded
About
InterveXion Therapeutics LLC operates as a clinical-stage biotechnology company based in Little Rock, Arkansas, specializing in innovative therapeutic development for substance use disorders. Founded in 2004 with technology licensed from the University of Arkansas for Medical Sciences, the company focuses on developing breakthrough treatments for methamphetamine addiction and overdose prevention. InterveXion Therapeutics manufactures and develops monoclonal antibody therapies designed to prevent methamphetamine from entering the central nervous system, effectively reducing the drug effects that drive addiction cycles. The company leading clinical asset, IXT-m200, represents a novel monoclonal antibody therapeutic that has received FDA Fast Track Designation for methamphetamine use disorder treatment. This proprietary manufacturing approach involves developing both short and long-acting antibody formulations and vaccine candidates that target methamphetamine molecules in the bloodstream. InterveXion Therapeutics maintains advanced bioprocessing capabilities for antibody production and purification, supporting their Phase 2 clinical development programs. With over 21.9 million dollars in federal grant funding from the National Institute on Drug Abuse and other agencies, InterveXion Therapeutics demonstrates strong regulatory compliance and manufacturing standards required for clinical-grade therapeutic production. The company biotechnology manufacturing platform supports scalable antibody production while maintaining rigorous quality control protocols essential for pharmaceutical development. InterveXion Therapeutics continues advancing their pipeline through strategic partnerships and collaborations, positioning themselves as leaders in addiction medicine manufacturing within the Arkansas biotechnology sector.